Bortezomib Global Buyers List: A Strategic Guide for API Suppliers and Procurement Teams
Bortezomib, a first-in-class proteasome inhibitor, remains a foundational therapy in the management of multiple myeloma and mantle cell lymphoma (MCL). Its mechanism of action—selectively inhibiting the 26S proteasome—disrupts protein degradation pathways in malignant plasma cells, leading to apoptosis and tumor suppression. As a result, Bortezomib plays a critical role in both frontline and relapsed/refractory settings, often in combination regimens with immunomodulators, corticosteroids, and chemotherapeutics.
For API manufacturers, exporters, and procurement professionals, identifying reliable Bortezomib buyers is a strategic imperative. This guide provides a comprehensive overview of the global Bortezomib buyers landscape, including trade data insights, key buyer categories, regional demand patterns, regulatory considerations, and actionable strategies for connecting with verified purchasers.
Understanding the Bortezomib Market Landscape
The global market for Bortezomib was estimated at US$21.1 Million and is expected to reach US$26.3 Million by 2032, growing at a CAGR of 3.2% over the analysis period. Injection, one of the segments analyzed, is expected to record a 2.6% CAGR and reach US$17.0 Million by the end of the analysis period, while growth in the Powder for Injection segment is estimated at 4.5% CAGR.
The U.S. market is estimated at US$6.5 Million, while China is forecast to reach a projected market size of US$6.0 Million, trailing a CAGR of 5.9%. Among other noteworthy geographic markets, Japan and Canada are forecast to grow at a CAGR of 1.6% and 2.7% respectively, while within Europe, Germany is forecast to grow at approximately 2.2% CAGR.
Demand remains highest in North America and Europe, where Bortezomib is a standard-of-care treatment. However, generic entry and biosimilar development are making Bortezomib more affordable and accessible, particularly in cost-sensitive markets. This expansion is particularly impactful in regions with high myeloma burden and constrained oncology resources, where Bortezomib-based regimens often represent the most accessible and effective treatment option.
Key Categories of Bortezomib Buyers
Bortezomib buyers span a diverse range of organizations across the pharmaceutical supply chain. Understanding these categories is essential for targeted outreach and relationship building.
Pharmaceutical Manufacturers and Formulators
Bortezomib is marketed by numerous pharmaceutical companies, including Accord Healthcare, Apotex, Baxter Healthcare Corp, Dr. Reddy’s, Eugia Pharma, Fresenius Kabi USA, Hetero Labs Ltd, Hospira, Jiangsu Hansoh Pharm, Meitheal, MSN, Pharmascience Inc, Qilu Pharm Hainan, Reliance Life Sci, Sandoz, Scinopharm Taiwan, Teva Pharms USA, and Zydus Pharms, among others. These organizations are primary buyers of Bortezomib API for the production of finished sterile drug products.
Generic Drug Companies
With the expiration of key patents, generic drug companies have entered the Bortezomib market. A generic version of Bortezomib was approved as bortezomib by Apotex, marking a significant milestone in the drug’s lifecycle. Generic manufacturers seek API suppliers that can provide cost-effective, high-quality Bortezomib to support their formulations.
Distributors and Trading Companies
Pharmaceutical distributors and trading companies play a crucial role in the Bortezomib supply chain. These organizations purchase API and finished products for redistribution to healthcare providers, pharmacies, and hospitals across various regions. Notable distributors include Medac GmbH & Co. KG (Germany) and Diempec CIA Ltda Distribuidora Farmaceutica (Ecuador).
Research Institutions and CDMOs
Contract Development and Manufacturing Organizations (CDMOs) and research institutions also purchase Bortezomib API for clinical trials, formulation development, and analytical testing. These buyers often require small quantities and may have specific quality and documentation requirements.
Compounding Pharmacies
Compounding pharmacies represent a niche but important segment of Bortezomib buyers. These organizations may require API for preparing customized formulations for specific patient needs.
Global Bortezomib Buyer Directory: Trade Data Insights
Trade data provides valuable intelligence on Bortezomib buyers and their procurement patterns. According to global trade databases, there are 525 buyers and 131 suppliers of Bortezomib worldwide. Bortezomib and HSN Code 30049049 export import data reveals 632 buyers across 110 countries.
Prominent Bortezomib Buyers by Region
| Buyer Name | Country | Transactions | Product Description |
|---|---|---|---|
| Hospira Australia | United States | 468 | BORTEZOMIB IHS |
| Medac GmbH & Co. KG | Germany | 247 | BORTEZOMIB |
| TPM Laboratories Inc. | United States | 189 | BORTEZOMIB (IMPURITY B) |
| Ever Pharma Jena GmbH | Germany | 214 | BORTEZOMIB (BZX) |
| Ever Valinject GmbH | Austria | 129 | BORTEZOMIB (3 GMS) |
| Revi Ve Health Care | Pakistan | 447 | BORTEZOMIB |
| PSM Pharmaceuticals Ltd. | Kenya | 1,576 | BORTEZOMIB |
| Minerva Scientific Ltd. | England | 270 | PLACEBO OF BORTEZOMIB |
| Bo Ryung Pharm Co. Ltd. | South Korea | 2 | BORTEZOMIB IHS |
| Pfizer Global Supply Japan Inc. | United States | 63 | BORTEZOMIB IMPURITY A |
Sources: 52wmb.com trade data
Trade Flow Analysis
India leads Bortezomib exports with a share of approximately 84%, while Argentina is a notable importer with a share of about 15%. The trade is dominated by API (Active Pharmaceutical Ingredient) and finished sterile drug products (vials for IV/SC dosing).
China’s Bortezomib import shipments have seen a diverse range of top exporting countries including Ireland, Indonesia, the UK, India, and Metropolitan France. China’s Bortezomib Injection export shipments stood at 21, exported by 8 China exporters to 13 buyers.
Regional Demand Patterns for Bortezomib
North America
The U.S. market represents a significant portion of Bortezomib demand, estimated at US$6.5 Million. Buyers in this region include major pharmaceutical manufacturers, generic drug companies, and distributors. The presence of multiple ANDA holders ensures sustained API demand.
Europe
Within Europe, Germany is forecast to grow at approximately 2.2% CAGR. European buyers include Medac GmbH & Co. KG, Ever Pharma Jena GmbH, and Ever Valinject GmbH, among others. The European Medicines Agency (EMA) has authorized multiple Bortezomib products, indicating a competitive market with diverse buyer requirements.
Asia-Pacific
China is forecast to grow at 5.9% CAGR, making it a key market for Bortezomib buyers. Japan and South Korea also represent important markets, with buyers such as Bo Ryung Pharm Co. Ltd. (South Korea) and Pfizer Global Supply Japan Inc..
Latin America
Argentina is a notable importer of Bortezomib API, with a share of approximately 15%. Laboratorios I.M.A. S.A.I.C. (Argentina) and MSD Argentina S.R.L. are among the buyers in this region.
Middle East and Africa
Buyers in this region include Revi Ve Health Care (Pakistan) and PSM Pharmaceuticals Ltd. (Kenya). These markets represent growing opportunities as Bortezomib becomes more accessible in lower- and middle-income countries.
Regulatory Considerations for Bortezomib Trade
Bortezomib is a regulated pharmaceutical product, and buyers must comply with stringent regulatory requirements. Understanding these requirements is essential for suppliers seeking to establish lasting relationships with global buyers.
FDA Requirements (United States)
In the United States, Bortezomib for Injection is approved for the treatment of patients with multiple myeloma and for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Bortezomib for Injection is a 505(b)(2) application referencing Velcade® as the reference listed drug.
Bortezomib supply chains typically split into (1) drug substance (API) and (2) finished sterile drug product (vials for IV/SC dosing). API is often sourced from specialized chemical producers with qualification by formulators and distributors.
EMA Requirements (Europe)
The European Medicines Agency has granted marketing authorizations for multiple Bortezomib products. For example, Bortezomib Logenex was granted marketing authorization pursuant to Article 10(1) of Directive 2001/83/EC. The EMA has concluded that Bortezomib Fresenius Kabi is of comparable quality to Velcade.
CDSCO Requirements (India)
As India is a leading exporter of Bortezomib, compliance with CDSCO (Central Drugs Standard Control Organisation) requirements is essential for suppliers in this region. Indian manufacturers such as Hetero Labs, Dr. Reddy’s, and Natco Pharma are active in the Bortezomib supply chain.
Documentation and Quality Standards
Bortezomib buyers typically require comprehensive documentation, including:
- Certificate of Analysis (CoA)
- Drug Master File (DMF)
- Good Manufacturing Practice (GMP) certification
- Regulatory approval documentation
- Stability data
- Impurity profiles
How to Find and Connect with Bortezomib Buyers
1. Leverage Trade Data Platforms
Trade data platforms such as Volza, Eximpedia, and 52wmb provide comprehensive Bortezomib import export data, including buyers and suppliers lists. These platforms allow suppliers to:
- Search for buyers by HS code (e.g., 30049049, 3004909900)
- Rank importers by volume
- Access complete Bill of Lading data with buyer and supplier names
- Identify procurement patterns and seasonal trends
2. Utilize Pharmaceutical B2B Marketplaces
Pharmaceutical B2B marketplaces such as Pharmaoffer connect API suppliers with global buyers. These platforms cover a wide range of buyer types including multinational manufacturers, generic drug companies, CDMOs, distributors, research institutions, and compounding pharmacies. Pharmaoffer can also enhance company visibility in search engines and modern AI procurement tools.
3. Optimize for Search and Answer Engines
For pharmaceutical manufacturing companies, a strong SEO strategy is essential to attract high-intent buyers. Key strategies include:
- Keyword Research: Prioritize both informational and commercial keywords associated with products, therapeutic areas, and export markets.
- On-Page Optimization: Optimize title tags, meta descriptions, H1/H2 structures, and internal linking.
- Compliance-Focused Content: Create content that addresses GMP, FDA, ISO, and WHO certifications to build trust with buyers.
- Answer Engine Optimization: Structure content to directly answer common procurement questions, such as “Who are the top Bortezomib buyers?” and “What are the regulatory requirements for Bortezomib API?”
4. Attend Industry Trade Shows and Conferences
Pharmaceutical trade shows and conferences provide opportunities to connect with Bortezomib buyers in person. Key events include CPHI Worldwide, BioPharma Asia, and AAPS Annual Meeting.
5. Build Direct Relationships with Generic Manufacturers
With the expiration of key Bortezomib patents, generic manufacturers are actively seeking reliable API suppliers. Building direct relationships with companies such as Apotex, Accord Healthcare, and Dr. Reddy’s can lead to long-term supply agreements.
Strategies for Success in the Bortezomib Market
Focus on Quality and Compliance
Quality and regulatory compliance are non-negotiable in the pharmaceutical API market. Suppliers must maintain GMP certification, provide comprehensive DMFs, and ensure consistent product quality to meet the stringent requirements of Bortezomib buyers.
Offer Competitive Pricing
With generic entry increasing competition, pricing has become a critical factor in Bortezomib procurement. Suppliers should develop value-based pricing strategies that balance profitability with market competitiveness.
Provide Technical Support
Bortezomib buyers often require technical support for formulation development, analytical testing, and regulatory submissions. Suppliers that offer comprehensive technical support can differentiate themselves in a crowded market.
Ensure Supply Chain Reliability
Supply chain reliability is a key concern for Bortezomib buyers, particularly given the drug’s critical role in oncology treatment. Suppliers should maintain robust inventory management systems and contingency plans to ensure uninterrupted supply.
Stay Informed About Market Trends
The Bortezomib market is dynamic, with ongoing developments in formulation technology, regulatory requirements, and competitive landscape. Suppliers should continuously monitor market trends, including:
- Subcutaneous administration preferences
- Dose-adjusted regimens
- Generic entry and biosimilar development
- Emerging markets and regulatory changes
Frequently Asked Questions
Who are the top Bortezomib buyers globally?
Top Bortezomib buyers include Hospira Australia, Medac GmbH & Co. KG, TPM Laboratories Inc., Ever Pharma Jena GmbH, Ever Valinject GmbH, Revi Ve Health Care, and PSM Pharmaceuticals Ltd.. Pharmaceutical manufacturers such as Accord Healthcare, Apotex, Dr. Reddy’s, and Hetero Labs are also significant buyers.
What is the HS code for Bortezomib?
Bortezomib is classified under several HS codes, including 30049049 and 3004909900. The specific HS code depends on the product form (API vs. finished dosage) and the importing country’s classification system.
Which countries are the largest importers of Bortezomib?
Argentina is a notable importer of Bortezomib API with a share of approximately 15%. China, the United States, and European countries are also significant importers.
How can I verify a Bortezomib buyer’s legitimacy?
Verify buyers through trade data platforms (Volza, Eximpedia, 52wmb), regulatory databases (FDA, EMA, CDSCO), and industry references. Request business licenses, import permits, and regulatory documentation before establishing a supply relationship.
What documentation do Bortezomib buyers typically require?
Bortezomib buyers typically require Certificate of Analysis (CoA), Drug Master File (DMF), GMP certification, regulatory approval documentation, stability data, and impurity profiles.
ADIUM PHARMA S A
LABORATORIO LIBRA SOCIEDAD ANONIMA
BIO TECH PHARMA SOCIEDAD ANONIMA
GADOR S A
EXTROVIS PRIVATE LIMITED
JOHNSON JOHNSON PRIVATE LIMITED
MSD ARGENTINA S R L
MINISTERIO DE SALUD
CÔNG TY TNHH DƯỢC PHẨM VIỆT PHÁP
MERCK LIFE SCIENCE PRIVATE LIMITED
CÔNG TY TNHH JOHNSON JOHNSON VIỆT NAM
JANSSEN CILAG SA
MEGA LABS SOCIEDAD ANONIMA
LABORATORIOS PHOENIX SAIC Y F
NOLVER S A
SEVEN PHARMA COLOMBIA S A S
ROEMMERS S A
BIOSIDUS SOCIEDAD ANONIMA
GLAXOSMITHKLINE URUGUAY S A
HEALTHCARE PHARMACEUTICALS LTD
MURRY S A
VEM ILAC SANAYI VE TICARET ANONIM SIRKETI
AMAROX PHARMA SA DE CV
LABORATORIO KEMEX SA
MSN LABS AMERICAS S A S
J J PRODUCTOS MEDICOS FARMACEUTICOS DEL PERU S A
LABORATORIOS IMA S A I C
ROCHE INTERNATIONAL LTD
SEVEN PHARMA SAC
TOKYO CHEMICAL INDUSTRY INDIA PRIVATE LIMITED
DR REDDY S LABS S A S
JANSSEN CILAG SA DE CV
MSN LABS PERU S A C
PT CKD OTTO PHARMACEUTICALS
TARGET SA
CAMBER PHARMACEUTICALS INC
EUGIA PHARMA SPECIALITIES LIMITED
HIMMEL PHARMACEUTICALS PVT LIMITED
JOHNSON Y JOHNSON DE CHILE SA
REVIVE HEALTH CARE
TANERA TRANSPORT LLC
AUROBINDO PHARMA COLOMBIA S A S
BRISTOL MYERS SQUIBB DE CHILE
CÔNG TY TNHH DƯỢC PHẨM VÀ TRANG THIẾT BỊ Y TẾ HOÀNG ĐỨC
NOVARTIS ARGENTINA S A
RICONPHARMA INDIA PRIVATE LIMITED
APOTEX S A
BAXALTA COLOMBIA S A S
BLAUFARMA URUGUAY SA
DORALBEN SA
DSV AIR SEA INC
ERNEST CHEMISTS LIMITED
EUROFARMA ARGENTINA S A
GRAMON BAGO DE URUGUAY S A
ICU VITA S A
MICROSULES ARGENTINA S A DE SERVICIOS COM IND INMB AGROPECUA
NUTRI MED SOCIEDAD ANONIMA
BOEHRINGER INGELHEIM S A
CÔNG TY TNHH SẢN XUẤT NAVIS VIỆT NAM
ICLOS URUGUAY S A
SCHMIDTS PHARMA S R L
SEVEN PHARMA DEL ECUADOR DISTRIBUIDORA COMERCIALIZADORA SEVENPHARMA S A
URUFARMA S A
XINETIX PHARMA S A S
BEACON PHARMACEUTICALS PLC
BIOMEDICAL LIFE SCIENCES
DOM FARMACEUTICA SA DE CV
ERIOCHEM S A
EUROFARMA URUGUAY SOCIEDAD ANONIMA
FRESENIUS KABI ONCOLOGY LIMITED
GLENMARK PHARMACEUTICALS LIMITED
HIMMEL PHARMACEUTICALS PVT LTD
JANSSEN CILAG FARMACEUTICA SOCIEDAD ANONIMA
JOHNSON Y JOHNSON DE URUGUAY S A
MSN LIFE CARE SA DE CV
PFIZER INC
PT DEXA MEDICA
RIPPLE PHARMACEUTICALS LIMITED
SUN PHARMACEUTICAL INDUSTRIES S A C
SYNTHON CHILE LIMITADA
SYNTHON MEXICO SA DE CV
TECNOFARMA COLOMBIA SAS
VIMTA LABS LIMITED
ТОО СК ФАРМАЦИЯ
ALLIANZ BIOINNOVATION
BIOTOSCANA URUGUAY S A
BIOXEL S A
CHI NHÁNH CÔNG TY CỔ PHẦN DƯỢC PHẨM THIẾT BỊ Y TẾ HÀ NỘI
GLENMARK GENERICS S A
M S ZAS CORPORATION
MEDSCRIBE LIMITED
NOREPLEY S A
OXIMIO LOJISTIK VE AMBALAJ SANAYI VE TICARET LIMITED SIRKETI
PPD GLOBAL LIMITED MERKEZI INGILTERE TURKIYE ISTANBUL SUBESI
PSM PHARMACEUTICALS LIMITED
PT FONKO INTERNATIONAL PHARMACEUTICALS
QUANTIQA BARION LTDA
SCANDINAVIA PHARMA LTDA
SIMBA PHARMACEUTICALS LIMITED
SUN PHARMA PHILIPPINES INC
AL HABIB PHARMACEUTICALS
BDR LIFESCIENCES PRIVATE LIMITED
BIOETHIC PHARMA SOCIEDAD ANONIMA
BRISTOL MYERS SQUIBB DE COL S A
DHL GLOBAL FORWARDING MI
DR REDDY S LABORATORIES LIMITED
DSV AIR SEA INC DBA DSV OCEAN
EL ALAMO SA
HETERO LABS LIMITED
HIKMA PHARMACEUTICALS USA INC
HOSPIRA WORLDWIDE INC
IQVIA TIBBI ISTATISTIK TICARET VE MUSAVIRLIK LIMITED SIRKETI
JOHNSON AND JOHNSON SIHHI MALZEME SANAYI VE TICARET LIMITED SIRKETI
LABORATORIO LKM S A
LIBRA PARAGUAY SA
M S HELIX PHARMA PVT LTD
ONCOPHARM U LTD
PROSALUD FARMA S A
QUIMFA S A
SEVEN PHARMA CHILE SPA
SITIO SALUD S A
AMGEN BIOTECNOLOGICA S A S
AUROVIDA FARMACEUTICA SA DE CV
BURNY S A
CHI NHÁNH CTY TNHH ZUELLIG PHARMA VIỆT NAM
CÔNG TY TNHH VẬT TƯ KHOA HỌC CÔNG NGHỆ T T
EAST CANTONMENTS PHARMACY LIMITED
HONIMELL S A
HOSPIRA INC
IVAX ARGENTINA SOCIEDAD ANONIMA
JOHNSON AND JOHNSON PRIVATE LIMITED
KOCAK FARMA ILAC VE KIMYA SANAYI ANONIM SIRKETI
KRISHNA CHEMISTS LIMITED
LAB DIAGNOSTIC SYSTEMS SMC PVT LIMITED
LABORATORIO JAYOR PANAMA
LABORATORIOS ABD LTDA
LOBA IMPORT EXPORT SRL
LOCKBOURNE ROHR ROAD HIKMA
M S A J MIRZA PHARMA PVT LTD
MARTIN DOW LIMITED
MEGALABS URUGUAY S A
NAIROBI ENTERPRISES LIMITED
NOVADOZ PHARMACEUTICALS LLC
ORIENTAL FARMACEUTICA INDUSTRIAL COMERCIAL E INMOBILIARIA SO
PARANA MEDICAL S A
PHARMASTAR INTL TRADING CORPORATION
SALETICLAB S A
STATE PHARMACEUTICALS CORPORARION
ZEUX LIFESCIENCES SA DE CV
ООО ОЗОН
ТОВ НКС ФАРМ 01103 М КИЇВ ВУЛ МИХАЙЛА БОЙЧУКА 6 ОФІС 103
ТОВ УКРФАРМГРУП 03035 М КИЇВ ПРОВ ХОМОВА ЯРОСЛАВА БУД 14 ЛІТЕРА А
ACCORD HEALTHCARE S A C
ADIUM URUGUAY SOCIEDAD ANONIMA
AL PHARMA SA
AMBICA INTERNATIONAL CORPORATION
AREGNO S A
BEACON LOGISTICS LLC
BRISTOL MYERS SQUIBB ILACLARI INC ISTANBUL SUBESI
BRISTOL MYERS SQUIBB INDIA PRIVATE LIMITED
CONEPRE SA DE CV
CRISKEY S A
CÔNG TY CỔ PHẦN DƯỢC TRUNG ƯƠNG 3 CHI NHÁNH HÀ NỘI
CÔNG TY CỔ PHẦN GONSA
DHL GLOBAL FORWARDING ISRAEL LTD
DIEMPEC CIA LTDA DISTRIBUIDORA FARMACEUTICA
DISTRIBUIDORA DROGUERIA SAGITARIO S R L
DR REDDY S LABORATORIES LTD
DR REDDYS LABORATORIES INC
FISHER BIOPHARMA SERVICES INDIA PVT LTD
FONKO INTERNATIONAL PHARMACEUTICALS
GBT GRUPO BIOTOSCANA SA
GEORGE STEUART HEALTH PVT LTD
GLENMARK PHARMACEUTICALS KENYA LIMITED
GLENMARK PHARMACEUTICALS MEXICO SA DE CV
GOLD TREE PHARMACEUTICALS LTD
HELM DE MEXICO SA
JSC RAFARMA
KHAIRI S A
LABORATORIOS ASPEN SA
LABORATORIOS LEGRAND SA
LABORATORIOS RICHMOND SACIF
LOCKBOURNE ROHR ROAD HIKMA PHARMACEUTICALS USA INC
MEDIWELL HEALTHCARE KENYA LIMITED
MEDSERV AFRICA LIMITED
MSN LABS CHILE SPA
MYLAN LABORATORIES LIMITED
NIPPON EXPRESS U S A INC
NORTHSTAR DISTRIBUTION CENTER
PHARMASTAR INTL TRADING CORP
PPD PHARMACEUTICAL DEVELOPMENT INDIA PRIVATE LIMIT
PT AMAROX PHARMA GLOBAL
PT MULTI EKA CHEMICALINDO
SAGENT
SAGENT C O EVERSANA LIFE SCIENCE SE
SANDOZ PHILS CORPORATION
SCORP MEDITECH LIMITED
SERVIMEDIC SOCIEDAD ANONIMA
SEVEN PHARMA PANAMA
SUN PHARMACEUTICAL INDUSTRIES LIMITED
SURYA PHARMA LIMITED
TEXAS CANCER CENTRE LIMITED
YUSEN LOGISTICS BENELUX BV
ГУ ЦЕНТР БЕЗОПАСНОСТИ ФАРМАЦЕВТИЧЕСКОЙ ПРОДУКЦИИ
ООО CHEMO LAB
ТОВАРИЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ АДВЕНА
2MG INCORPORATED
A J MIRZA PHARMA PRIVATE LIMITED
ACCORD HEALTHCARE LIMITED PH BRANCH
ACCORD HEALTHCARE LIMITED PHILIP
ACCORD HEALTHCARE LIMITED PHILIPPINE BRANCH OFFICE
AIC ENTERPRISES PRIVATE LIMITED
AJ MIRZA PHARMA PVT LTD
ALIMBER S A
AMBICA INT L CORP
AMGOMED
ASN CORPORATION
BIEM ILAC SANAYI VE TICARET ANONIM SIRKETI
BIOMEDICA SUPPLY CA
BIOPROFARMA SA
BIOTENG S A
BLAU FARMACEUTICA COLOMBIA SAS
CHEMIKALIE PHARMA TRADE S A
COMERCIAL FARMACEUTICA LEISA SOCIEDAD AN
COMPAÑIA ERWITAL SOCIEDAD ANONIMA
CONTRERAS ASOC CONSULTORES INT
COSPHARM INVESTMENTS PTY LTD
CRACK MOTORS SRL
CYGEN LABS LTDA
CÔNG TY TNHH THƯƠNG MẠI DƯỢC PHẨM NAM NGUYÊN
CÔNG TY TNHH ZUELLIG PHARMA VIỆT NAM
CÔNG TY TRÁCH NHIỆM HỮU HẠN SINH DƯỢC PHẨM HERA
D H L KEELS PVT LTD
DANUBE LOGISTICS USA INC
DANZAS CORPORATION DBA DHL GLOBAL FORWARDING
DEVA HOLDING ANONIM SIRKETI
DHL GLOBAL FORWARDING SPAIN SL MAD
DR REDDY S LABORATORIES CANADA INC
DR REDDY S LABORATORIES INC
DR REDDYS LABORATORIES
EAST CANTONMENTS PHARMACY LTD
EKA BIOLAB TEKNOLOJI KIMYA TICARET LIMITED SIRKETI
EMCURE PHARMACEUTICALS LIMITED
EUGIA PHARMA COLOMBIA SAS
EVERON LIFE SCIENCES
EXELTIS S A S
FRESENIUS KABI CHILE LIMITADA
FRESENIUS KABI COLOMBIA SAS
FRESENIUS KABI S A
G P PHARM SA
GADOR S A S
GALAXY PHARMACEUTICAL LIMITED
GENERICS SPECIALITIES LTD
GLENMARK PHARMACEUTICALS COLOMBIA S A S
GRUPO MULTILAB SOCIEDAD ANONIMA
HB HUMAN BIOSCIENCE S A C
HB HUMAN BIOSCIENCE S A S
HEALTH SERVICES
HIMMEL PAHRAMCEUTICALS PVT LTD
INGENUS PHARMACEUTICALS LLC
INSPIRE PHARMACEUTICALS LIMITED
INTELIGENCIA EN SOLUCIONES REGULATORIAS SA DE CV
JSC GRAND PHARM TRADE
KENT PHARMACEUTICALS KENYA LIMITED
KPI HEALTHCARE LIMITED
KPI HEALTHCARE LIMITED KAMPALA NAKAWA DIVISION NAKAWA DIVISION NTINDAVILLAGE 12 NTIDA STRETCHER KPI HEALTHCARE LIMITED
KWALITY PHARMACEUTICALS LIMITED
LABORATORIO GADOR S A
LABORATORIOS AMERICANOS S A
LABORATORIOS LA SANTE SA
LOCKBOURNE ROHR ROAD HIKMA PHAR
LOCKBOURNE ROHR ROAD HIKMA PHARM
M S LAB DIAGNOSTIC SYSTEM PVT LTD
MARTIN DOW MARKER LIMITED
MEDFORTE PHARMACEUTICALS
MEGA LABS COMPRAS
MEGA LIFESCIENCES LIMITED INC
MERCK SA DE CV
MERILINE LOGISTICS LIMITED
MEROS PHARM
MINISTRY OF HEALTH OF GHANA
NATIONAL DRUG SERVICE ORGANISATION
NEXT PHARMA SOURCING S A S
NORTHSTAR DISTRIBUTION CENTER 8912
OOO ASTOR ALLIANCE
OOO EVER NEURO PHARMA
PFIZER CHILE S A
PILL PACK HEATHCARE LIMITED
PRODUCTOS ROCHE S A QUIMICA E INDUSTRIAL
PT PRATAPA NIRMALA
QUIMICOS E INSUMOS INDUSTRIALES DE MEXICO SA DE CV
R N VISION PHARMA PRIVATE LIMITED
RELATIONS INTERNATIONAL LIMITED
RENATA LTD CHANGE FROM PFIZER
ROEMMERS SACI
ROHLIG USA LLC
ROYAL MEDICAL PRIVATE LIMITED
SAGENT PHARMACEUTICALS INC1901 N
SAKAR HEALTHCARE LIMITED
SARTORIUS STEDIM INDIA PRIVATE LIMITED
SCAVONE HERMANOS SA
SCORPIO SOLUTIONS LIMITED
SEVEN PHARMA NICARAGUA S A
SHILPA PHARMA LIFESCIENCES LIMITED
SIMSON PHARMA LIMITED
SMO TU LOJISTIK VE AMBALAJ SANAYI VE TICARET LIMITED SIRKETI
SOLARISBOLIVIA SRL
SUN PHARMA CANADA INC
SYNGENE SCIENTIFIC SOLUTIONS LIMITED
TASSOS S A
TEVA LIMITED LIABILITY COMPANY
THE EAH CARE LIMITED
THERMO FISHER SCIENTIFIC INDIA PRIVATE LIMITED
TUTEUR SOCIEDAD ANONIMA
UGANDA CANCER INSTITUTE
UGANDA CANCER INSTITUTE KAMPALA KAWEMPE DIVISION SOUTH KAWEMPE DIVISION MULAGO COMPLEX MULAGO UPPER
UPS SUPPLY CHAIN SOLUTIONS INC
V M G HEALTHCARE PRODUCTS SOCIEDAD ANONIMA
VMG HEALTH CARE PRODUCTS S A
XINEPHARMA S A
ООО DRUG PROMOTION
ООО ОЗОН ФАРМ
ООО ЭВЕР НЕЙРО ФАРМА
ТОВ БУСТ ФАРМА 03022 М КИЇВ ВУЛ ВАСИЛЬКІВСЬКА 30
Conclusion
The global Bortezomib buyers market presents significant opportunities for API suppliers and exporters. With the market projected to grow steadily, driven by increasing demand for multiple myeloma and MCL treatments, suppliers that prioritize quality, compliance, and strategic buyer engagement will be well-positioned for success.
By leveraging trade data platforms, optimizing for search and answer engines, attending industry events, and building direct relationships with manufacturers, suppliers can effectively identify and connect with Bortezomib buyers worldwide. Understanding regulatory requirements across key markets—including the FDA, EMA, and CDSCO—is essential for maintaining compliance and building trust with buyers.
As the Bortezomib market continues to evolve, suppliers should stay informed about emerging trends, including formulation advancements, generic entry, and expansion into lower- and middle-income countries. By adopting a proactive and strategic approach, suppliers can capture a share of this growing market and contribute to improving access to this critical oncology treatment worldwide.


